| References: |
ONO-4059 is a highly potent and dual oral Btk/Tec inhibitor with an IC50 in the sub-nmol/L range. Previous studies with ONO-4059 demonstrated that ONO-4059 significantly inhibits the macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL)-driven osteoclast defferentiation. The treatment with ONO-4059 also resulted in a dose-dependent inhibition of arthritis severity and bone damage in a mouse collagen induced arthritis (CIA) model (ACR 2012).Btk and Tec are required for osteoclast differentiation and activation based on the genetic evidence obtained from Btk and Tec double deficient mice. Dual Btk/Tec inhibitor, ONO-4059 may be a novel therapeutic target for RA to suppress bone erosion and inflammation. For the detailed information of ONO-4059, the solubility of ONO-4059 in water, the solubility of ONO-4059 in DMSO, the solubility of ONO-4059 in PBS buffer, the animal experiment (test) of ONO-4059, the cell expriment (test) of ONO-4059, the in vivo, in vitro and clinical trial test of ONO-4059, the EC50, IC50,and affinity,of ONO-4059, For the detailed information of ONO-4059, the solubility of ONO-4059 in water, the solubility of ONO-4059 in DMSO, the solubility of ONO-4059 in PBS buffer, the animal experiment (test) of ONO-4059, the cell expriment (test) of ONO-4059, the in vivo, in vitro and clinical trial test of ONO-4059, the EC50, IC50,and affinity,of ONO-4059, Please contact DC Chemicals. |
